Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1759720X16673786 http://scihub22266oqcxt.onion/10.1177/1759720X16673786 C5315225!5315225!28255338     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Musculoskelet+Dis 2017 ; 9 (2): 45-53 Nephropedia Template TP {{tp|p=28255338|t=2017. Apremilast in the treatment of psoriatic arthritis: a perspective review |pdf=|usr=}}{{28255338}} gab.com Text Apremilast in the treatment of psoriatic arthritis: a perspective review JO: Ther Adv Musculoskelet Dis http://www.kidney.de/pget.php?&tw=1&pmid=28255338 #FOAvip Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease. Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy. We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA. Twit Text FOAVip Apremilast in the treatment of psoriatic arthritis: a perspective review ????Ther Adv Musculoskelet Dis http://www.kidney.de/pget.php?&tw=1&pmid=28255338 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28255338 #FOAvip English Wikipedia <ref>{{Cite pmid|28255338}}</ref> Apremilast in the treatment of psoriatic arthritis: a perspective review #MMPMID28255338 Reed M; Crosbie D Ther Adv Musculoskelet Dis 2017[Feb]; 9 (2): 45-53 PMID28255338show ga Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease. Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy. We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA. äApremilast in the treatment of psoriatic arthritis: a perspective revi(epmc).pdf DeepDyve Pubget Overpricing